% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. Message Board

  • wilderguide wilderguide Jul 24, 2013 1:27 PM Flag

    Ganetespib/Docetaxel combo improves OS in pre specified pops

    Dr Suresh Ramalingam at targetedhcdotcom 7/24/13 on HSP90i with Ganetespib.

    "An extension phase of GALAXY-1, focusing on biomarker analysis, recently completed accrual, with results expected to be reported later this year. In addition, the phase III GALAXY-2 trial will compare second-line ganetespib plus docetaxel versus docetaxel alone in advanced lung cancer patients with adenocarcinoma histology and will only enroll patients who are more than 6 months past a diagnosis of advanced disease. The target enrollment is 500 patients, and the primary endpoint is overall survival."

    I'm with this guy. I think SNTA has powered this extension cohort to unquestionably tease out a statsig OS signal in adv lung cancer populations with histologic adenocarcinoma.

0.3430.000(0.00%)Jul 22 4:00 PMEDT